 | |
| Clinical data | |
|---|---|
| Other names | (cis)-LR-5182, (cis)-LR-5182 hydrochloride |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H23Cl2N |
| Molar mass | 312.28 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
LR-5182 is astimulant drug which acts as anorepinephrine–dopamine reuptake inhibitor, structurally related to the better known drugfencamfamine.[1][2][3] It was developed by the pharmaceutical companyEli Lilly in the 1970s, and researched for potential use as anantidepressant, although never marketed. LR-5182 has twostereoisomers, both of which are active, although one isomer blocks reuptake of only dopamine and noradrenaline, while the other blocks reuptake of serotonin as well.[4]
While LR-5182 itself never proceeded beyond initial animal studies, discovery of monoamine reuptake inhibition activity and stimulant effects in drugs of this type has subsequently led to the development of many other stimulant drugs of related chemical structure, primarily developed as potential antidepressants,[5] or as substitute drugs for the treatment ofcocaine abuse.[6][7]
